Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Xianjing Chu, Wentao Tian, Ziqi Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Hao Lin, Chaxian Liu, An-Kang Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 59
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 29
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Antonino Glaviano, Hannah Lau, Lukas M. Carter, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 5
Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases
Wei Guo, Bolun Zhou, Lizhou Dou, et al.
Experimental & Molecular Medicine (2025)
Open Access | Times Cited: 3
The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components
Peng Zhang, Yuting Wang, Qianru Miao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115569-115569
Open Access | Times Cited: 23
Regulatory T cells in immune checkpoint blockade antitumor therapy
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2024) Vol. 593, pp. 216969-216969
Closed Access | Times Cited: 11
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Amdare, et al.
Biology (2024) Vol. 13, Iss. 5, pp. 307-307
Open Access | Times Cited: 9
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
Shreya Badhrinarayanan, Christopher Cotter, Huaqi Zhu, et al.
Future Oncology (2024) Vol. 20, Iss. 28, pp. 2049-2057
Open Access | Times Cited: 8
TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial
Aung Naing, Meredith McKean, Anthony W. Tolcher, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010584-e010584
Open Access | Times Cited: 1
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care
Yao Xiao, Zi‐Zhan Li, Nian‐Nian Zhong, et al.
Translational Oncology (2023) Vol. 38, pp. 101794-101794
Open Access | Times Cited: 16
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Abdullah Younis, John G. Gribben
Immuno (2024) Vol. 4, Iss. 3, pp. 186-210
Open Access | Times Cited: 7
Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution
Xuechao Liu, Jing Yu, Yi Li, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 6
CD155 and its receptors in cancer immune escape and immunotherapy
Ruijia Zhou, Shiyin Chen, Qiwen Wu, et al.
Cancer Letters (2023) Vol. 573, pp. 216381-216381
Closed Access | Times Cited: 15
VISTA: a novel checkpoint for cancer immunotherapy
Yu Gao, Yanting He, Yuanyuan Tang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104045-104045
Closed Access | Times Cited: 5
Prolyl isomerase Pin1 sculpts the immune microenvironment of colorectal cancer
Yang Li, Zhongnan Yuan, Linlin Wang, et al.
Cellular Signalling (2024) Vol. 115, pp. 111041-111041
Closed Access | Times Cited: 4
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns
M. Korpan, Hannah Christina Puhr, J.M. Berger, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 340-340
Open Access
Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
Yuxiang Huang, Hengjian Liao, Jiefu Luo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Multiple machine learning-based integrations of multi-omics data to identify molecular subtypes and construct a prognostic model for HNSCC
Xiaoqin Luo, Chao Li, Gang Qin
Hereditas (2025) Vol. 162, Iss. 1
Open Access
The Role of the Tumor Microenvironment in Tumor Progression and Response to Therapy
Rafal Salim, Watheq Mohammed AL-Jewari
(2025) Vol. 1, Iss. 1, pp. 9-14
Closed Access
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors
Fei Du, Guojun Wang, Qian Dai, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment
Wonjun Son, Yangsoon Lee, Yelim Park, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010728-e010728
Open Access
AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies
Astrid Musnier, Yannick Corde, A. Verdier, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
New insights into cancer immune checkpoints landscape from single-cell RNA sequencing
Qian Wang, Jiahui He, Tianyu Lei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 3, pp. 189298-189298
Closed Access
Page 1 - Next Page

Scroll to top